J&J reports analysis from Phase III trial of plaque psoriasis treatment

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in treating moderate-to-severe plaque psoriasis (PsO).